selpercatinib

Selpercatinib is prescribed for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) that has already spread, specifically in cases where the tumors have RET fusion-positive genes. Prior to starting this medication, your doctor will conduct a test to determine if the RET gene fusion is present.

Selpercatinib, marketed as Retevmo and other brand names, is a drug used to treat cancer in individuals with tumors that have a genetic alteration (mutation or fusion) in the RET gene, which stands for “rearranged during transfection.”

Information on Retevmo (selpercatinib) including dosage, uses, potential drug interactions, side effects, and additional details.

Selpercatinib acts as an inhibitor of Rearranged during Transfection (RET), Cytochrome P450 2C8, Cytochrome P450 3A, P-Glycoprotein, Breast Cancer Resistance Protein, and Multidrug and Toxin Extrusion Transporter 1.

Palladium-based anticancer drugs encompass a variety of compounds that incorporate the platinum group metal (PGM), palladium, in different forms such as metallic palladium (Pd(0)) and palladium ions with oxidation states of 2+ or 4+. Furthermore, cancer therapeutics have also utilized the radioactive isotope 103Pd.

Pralsetinib, marketed as Gavreto, is an approved medication for the treatment of medullary thyroid cancer (MTC) with RET mutations and differentiated thyroid cancer (DTC) with RET fusions that are resistant to radioactive iodine (RAI) therapy.

Cisplatin has multiple mechanisms for its anticancer activity, but the most widely accepted mechanism involves creating DNA lesions by interacting with purine bases on DNA. This interaction then activates several signal transduction pathways, ultimately leading to apoptosis.

Pralsetinib, a targeted therapy, effectively inhibits the protein RET, which is associated with uncontrolled cell growth and cancer. By blocking RET fusions, this medication can effectively slow down or halt tumor growth.

Retevmo is a treatment option that can be taken at home and is not classified as chemotherapy, immunotherapy, or radiation therapy.

Retevmo (selpercatinib) belongs to the multikinase inhibitors drug class and is typically prescribed for Non-Small Cell Lung Cancer, Solid Tumors, and Thyroid Cancer. The price for a 60-capsule supply of Retevmo oral capsules (80 mg) is approximately $11,181, but may vary depending on the pharmacy.

Selpercatinib, a kinase inhibitor, is currently being marketed under the brand name RETEVMO by Loxo Oncology Inc. It has also received approval from the European Commission.

Selpercatinib is classified as an antineoplastic medication, which falls under the category of cancer medicines. Its mechanism of action involves inhibiting the growth of cancer cells, leading to their eventual elimination. It is important to note that this medication can only be obtained with a valid prescription from your doctor.

Selpercatinib belongs to a group of drugs known as kinase inhibitors. Its mechanism of action involves inhibiting the activity of an abnormal protein that stimulates the proliferation of cancer cells. This action aids in impeding or halting the dissemination of cancer cells.

Upon oral administration, selpercatinib specifically binds to and targets different RET mutants and fusion products containing RET. This leads to the suppression of tumor cell growth in cells with heightened RET activity.

If you experience any severe side effects, it is important to inform your doctor immediately. These may include easy bruising or bleeding, slow healing of wounds, symptoms indicating an underactive thyroid such as weight gain, excessive fatigue, or intolerance to cold temperatures, as well as signs of liver disease like persistent nausea or vomiting, loss of appetite, or stomach and abdominal pain.

Taxol, also known as paclitaxel, is a type of chemotherapy drug that belongs to the class of Taxane chemotherapy. Other taxanes include Abraxane and Taxotere.

Discovered in the 1960s, Paclitaxel (Taxol) is a chemotherapy drug that inhibits the growth of cancer cells by disrupting their ability to divide. It is commonly used to treat a variety of cancers, including breast, ovarian, and lung cancers.

Corticosteroids, also known as steroids, are natural hormones and hormone-like medications that are beneficial in treating various types of cancer and other medical conditions. When used in cancer treatment, they are classified as chemotherapy drugs. Prednisone is an example of a corticosteroid.

In the safety analysis set, which included a total of 702 patients treated with selpercatinib, the most frequently observed treatment-related adverse events (TRAEs) were dry mouth (33.3%), increased AST (24.5%), increased ALT (23.8%), hypertension (23.2%), diarrhea (19.7%), and fatigue (16.8%), occurring in at least 15% of patients.

Cisplatin and paclitaxel, also referred to as “cis/taxol,” are administered to reduce tumor size and alleviate symptoms associated with cervical cancer. However, it is not typically used with the intention of curing the cancer.

Regardless of disease type, the phase 1/2 portion of the trial found that fatigue (20%), diarrhea (17%), and bruising (13%) were the most commonly reported side effects by patients. This portion of the trial included patients with chronic lymphocytic leukemia (CLL), small lymphocytic leukemia, and Waldenstrom’s macroglobulinemia.

After a median follow-up period of approximately 19 months, participants who were treated with selpercatinib experienced a median progression-free survival of 24.8 months, while those in the chemotherapy group had a median progression-free survival of 11.2 months.

Typically, stage 4 cancer has metastasized to various parts of the body, resulting in a life expectancy of a few weeks to a few months. However, there are rare instances where individuals may survive for several months or even a year, with or without treatment.

Stage 4 cancer, also known as metastatic cancer, is an advanced form of the disease where the cancer has spread from its original location to nearby organs or other distant parts of the body. While expert care is necessary for this advanced stage, some people may live for several years after receiving treatment.

The five-year survival rate for individuals with early-stage, surgically treatable Pancoast tumors ranges from 30% to 50%.

The prognosis for individuals with a terminal illness can vary greatly, ranging from a few days to several years. The duration of their life largely depends on their specific diagnosis and the treatments they are undergoing. Healthcare professionals often face challenges in accurately predicting the exact lifespan of someone with a terminal illness.

The Median Duration of Response provides an estimate of how long your cancer will continue to respond to chemotherapy before it begins to grow again. This duration typically falls between 3 to 12 months for cancers treated with palliative chemotherapy. A longer response duration indicates a potentially longer life expectancy.

The overall response rate (ORR) with Retevmo as assessed by BICR was 83.7% (95% CI: 76.2, 89.6), which was significantly higher compared to the control arm’s ORR of 65.1% (95% CI: 53.8, 75.2). These findings were consistent across all pre-specified subgroups and were also observed in the ITT population for both BICR and investigator-assessed endpoints.

TABRECTA has been shown to reduce tumor size in first-time users. In a study of 60 previously untreated individuals, 68% experienced a positive response to TABRECTA.

Out of the 963 patients who underwent palliative radiotherapy, only 2.4% (n = 23) managed to survive for a minimum of 5 years. Among these survivors, a significant majority (73.9%, n = 17) were found to be disease-free.

The median survival for patients with ECOG 0 was 293 days (95% CI, 242 to 403 days), for ECOG 1 it was 197 days (95% CI, 183 to 219 days), for ECOG 2 it was 104 days (95% CI, 90 to 118 days), for ECOG 3 it was 55 days (95% CI, 46 to 66 days), and for ECOG 4 it was 25.5 days (95% CI, 17 to 51 days).

The Alecensa treatment is typically administered until the patient experiences disease progression or encounters intolerable side effects. It is specifically prescribed for the treatment of ALK-positive non-small cell lung cancer (NSCLC) that has metastasized to other areas of the body.

On September 21, 2022, Eli Lilly and Company’s drug, Retevmo (selpercatinib), received accelerated approval from the FDA. This approval allows for the treatment of adult patients who have locally advanced or metastatic solid tumors with a RET gene fusion. These patients must have either experienced progression on or after prior systemic treatment or have no other available treatment options.

Information on Retevmo (selpercatinib) including dosage, uses, potential drug interactions, side effects, and additional details.

Pembrolizumab, the first drug to receive approval for a tumor-agnostic indication, is an immunotherapy medication that functions by removing the inhibitory mechanisms on the immune system.

On September 21, 2022, the FDA granted approval for selpercatinib to treat solid tumors that are locally advanced or metastatic and positive for RET fusion.

On May 19, 2022, Selpercatinib was granted Orphan Drug Designation for the treatment of tissue-agnostic RET fusion-positive solid tumors. Just 12 days later, on May 31, 2022, a supplemental new drug application (sNDA) was submitted. The sNDA review process utilized the Assessment Aid to assist with FDA review and was given Priority Review designation.

The FDA granted approval to selpercatinib in September 2022 for the treatment of adult patients who have locally advanced or metastatic solid tumors with a RET gene fusion and have either failed previous systemic treatment or have no other viable treatment options. This decision was based on the results of the LIBRETTO- study.

Tumour agnostic treatment is a treatment approach that uses genomic information to identify new targets for therapy, regardless of the tumour’s histological origin. This treatment strategy typically meets the following requirements: the tumour has at least one molecular alteration, and these alterations are likely to predict the tumour’s response to therapy.

Eli Lilly and Company has received marketing authorization from the European Medicines Agency (EMA) for Retsevmo® (selpercatinib). This medication is now approved as a first-line monotherapy for the treatment of advanced non-small cell lung cancer (NSCLC) in adults with rearranged during transfection (RET) fusion-positive tumors.